Get started
Aldeyra Therapeutics, Inc.Aldeyra Therapeutics, Inc.Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

ALDX trade ideas

ALDX Announces Positive Top-Line Symptom and Sign ResultsAldeyra Therapeutics Announces Positive Top-Line Symptom and Sign Results from Run-In Cohort of Phase 3 TRANQUILITY Trial in Dry Eye Disease Statistical Significance of Reproxalap Over Vehicle Achieved for Ocular Redness, an FDA-Approvable Sign, and Clinical Symptoms of Ocular Dryness and Discomfort Acute Improvement in Ocular Redness and Symptom Scores Demonstrated Within Minutes of Reproxalap Administration in Dry Eye Chamber Main Cohort of TRANQUILITY Expected to Begin Enrollment in February 2021, Following Completion of Tear RASP Analysis and Finalization of Trial Design finance.yahoo.com
NASDAQ:ALDX
by AlenCiken
$ALDX Phase 2 results on May 1st stock could soar.Sentiment has been very positive in ALDEYRA THERAPEUTICS having already released positive results for other pipeline drugs. On may 1st phase 2 results for its new Dry Eye Syndrome drug will be presented and optimism is high on the rumor mill. The current price target by 7 analysts covering the name is $31 which is considerable higher than current levels. Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson Syndrome. The company is also developing other product candidates for proliferative vitreoretinopathy and other retinal diseases, post-transplant lymphoproliferative disease, autoimmune disease, metabolic disease, and cancer. None of Aldeyra's product candidates have been approved for sale in the U.S. or elsewhere.
NASDAQ:ALDXLong
by DEXWireNews